- Home
- MPB vs PLRX Comparison
MPB vs PLRX Comparison
Compare MPB & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PLRX
- Stock Information
- Founded
- MPB 1868
- PLRX 2015
- Country
- MPB United States
- PLRX United States
- Employees
- MPB N/A
- PLRX N/A
- Industry
- MPB Major Banks
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PLRX Health Care
- Exchange
- MPB Nasdaq
- PLRX Nasdaq
- Market Cap
- MPB 675.9M
- PLRX 93.3M
- IPO Year
- MPB N/A
- PLRX 2020
- Fundamental
- Price
- MPB $27.80
- PLRX $1.57
- Analyst Decision
- MPB Buy
- PLRX Hold
- Analyst Count
- MPB 2
- PLRX 11
- Target Price
- MPB $34.50
- PLRX $3.93
- AVG Volume (30 Days)
- MPB 187.5K
- PLRX 590.0K
- Earning Date
- MPB 10-24-2025
- PLRX 11-06-2025
- Dividend Yield
- MPB 2.88%
- PLRX N/A
- EPS Growth
- MPB N/A
- PLRX N/A
- EPS
- MPB 2.30
- PLRX N/A
- Revenue
- MPB $191,454,000.00
- PLRX N/A
- Revenue This Year
- MPB $25.28
- PLRX N/A
- Revenue Next Year
- MPB $28.41
- PLRX N/A
- P/E Ratio
- MPB $12.08
- PLRX N/A
- Revenue Growth
- MPB 13.34
- PLRX N/A
- 52 Week Low
- MPB $22.50
- PLRX $1.10
- 52 Week High
- MPB $33.87
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- MPB 38.21
- PLRX 52.57
- Support Level
- MPB $26.97
- PLRX $1.45
- Resistance Level
- MPB $28.82
- PLRX $1.59
- Average True Range (ATR)
- MPB 0.76
- PLRX 0.08
- MACD
- MPB -0.18
- PLRX 0.01
- Stochastic Oscillator
- MPB 24.65
- PLRX 73.51
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.